Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994-2018).
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5935
Abstract: OBJECTIVE To analyze the incidence, incidence trends, and survival of marginal zone lymphomas (MZLs) in Girona and to describe these indicators based on the location in the case of extranodal MZLs. METHODS Population-based study of… read more here.
Keywords: incidence; 100 000; survival marginal; mzl ... See more keywords
Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx025
Abstract: Background Localized early-stage extra-nodal marginal zone lymphoma (MZL) presents with heterogeneous organ involvement and is treated with various modalities, including resection, radiotherapy, and systemic therapy. We report the long-term outcome of a large cohort of… read more here.
Keywords: mzl; treatment; disease; relapse ... See more keywords
The Role of Molacular Genetic Examination in Differential Diagnosis and Prognostic Prediction in Patints with B-Cell Chronic Lymphoproliferative Disorders: A Restrospective Study of 1592 Patients
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-114920
Abstract: Background: B-cell chronic lymphoproliferative disorders (BCLPD) are a heterogeneous group of mature B-cell malignancies characterized by monoclonal proliferation in the bone marrow (BM) or peripheral blood (PB). The overlapped clinical features and the lack of… read more here.
Keywords: mzl; cll; diagnosis; prognostic prediction ... See more keywords
Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-118364
Abstract: Background/Objective: Marginal zone B-cell lymphomas (MZL) represent a heterogeneous group of indolent lymphomas, comprising of MALT lymphomas, nodal MZL and splenic MZL. Currently, there has been no widely accepted prognostic indices for these lymphomas. Recently,… read more here.
Keywords: mzl; cohort; malt ipi; consultancy honoraria ... See more keywords
Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-130384
Abstract: Background MZL is a low-grade non-Hodgkin's lymphoma (NHL) which involves lymph nodes, extranodal sites, or spleen. It is sensitive to radiation therapy, which is used in localized disease with curative intent. Yttrium-90 ibritumomab tiuxetan [(90)Y-IT;… read more here.
Keywords: mzl; treatment; non; time ... See more keywords
Does Hispanic Origin Affect the Repartition and Outcome of Marginal Zone Lymphoma?
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-136220
Abstract: BACKGROUND Marginal zone lymphoma (MZL) is a rare indolent lymphoma that represents about 7% of all Non-Hodgkin's lymphoma (NHL). MZL is divided into 3 subtypes with different repartition based on primary anatomical site: 60% extra-nodal… read more here.
Keywords: smzl; repartition; lymphoma; marginal zone ... See more keywords
Real World Patient Diagnostic and Treatment Patterns in Marginal Zone Lymphoma (MZL): First Results of the Prospective National MZL Registry of the German Lymphoma Alliance
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200798
Abstract: Background: Despite being the third most frequent B-cell lymphoma, marginal zone lymphoma (MZL) has been largely underrepresented in prospective clinical trials and registries. Based on this we initiated a prospective publicly funded registry for MZL… read more here.
Keywords: treatment; mzl; real world; lymphoma ... See more keywords
Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-202721
Abstract: Introduction Although MZL is an indolent B-cell lymphoma typically associated with excellent overall survival (OS), a subgroup of patients (pts) experience histological transformation (HT) to an aggressive lymphoma, significantly compromising their OS. Prior studies evaluating… read more here.
Keywords: diagnosis; mzl; high ki67; risk ... See more keywords
Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1003
Abstract: Background:Mosunetuzumab (Mosun) is a CD20xCD3 bispecific antibody with high efficacy in treatment of relapsed/refractory follicular lymphoma (FL). It is studied as first-line treatment alone or with lenalidomide (Len), an immunomodulator which may enhance T-cell effector… read more here.
Keywords: mzl; mosun; response; augmentation ... See more keywords
Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5350
Abstract: Introduction: There is no established standard of care for relapsed or refractory (R/R) marginal zone lymphoma (MZL). Zanubrutinib, a second generation covalent BTK inhibitor, was approved for R/R-MZL based on the results of the phase… read more here.
Keywords: mzl; response; lot; relapsed refractory ... See more keywords
Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7121
Abstract: Introduction Existing studies have demonstrated that combining BTK inhibitors with anti-CD20 monoclonal antibodies yields favorable outcomes in marginal zone lymphoma (MZL). As the first BTK inhibitor approved for MZL in China, orelabrutinib is expected to… read more here.
Keywords: treatment; orelabrutinib; mzl; response ... See more keywords